[Characterization of atrial fibrillation burden using wearables].
Charakterisierung der Vorhofflimmerlast mittels Wearables.
1‑channel ECG
Atrial fibrillation
Digital health
Photoplethysmography
Wearable electronic devices
Journal
Herzschrittmachertherapie & Elektrophysiologie
ISSN: 1435-1544
Titre abrégé: Herzschrittmacherther Elektrophysiol
Pays: Germany
ID NLM: 9425873
Informations de publication
Date de publication:
09 Feb 2024
09 Feb 2024
Historique:
received:
16
12
2023
accepted:
16
01
2024
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
9
2
2024
Statut:
aheadofprint
Résumé
The characterization of atrial fibrillation (AF) according to current guidelines categorically refers to the differentiation between paroxysmal, persistent, and permanent AF. A more precise characterization of AF, including the evaluation of AF burden, is playing an increasingly significant role in both scientific research and clinical practice. Digital devices, especially those with the capability of passive (semi-)continuous recording, can contribute to a more accurate quantification of AF burden. Particularly in patients with an already established diagnosis of AF, the evaluation of AF burden can be used to monitor the success of antiarrhythmic therapy including antiarrhythmic drugs or pulmonary vein isolation. However, important questions remain unanswered: In addition to a uniform, evidence-based definition of AF burden, clinically relevant cut-offs for AF burden and resulting therapeutic consequences (e.g., subclinical AF) need to be elaborated. Furthermore, the establishment and evaluation of care structures for assessing and integrating AF burden in clinical care, especially by incorporating data from wearable medical devices, should take place. Die Charakterisierung von Vorhofflimmern (VHF) entsprechend der aktuellen Leitlinien bezieht sich kategorisch auf die Differenzierung zwischen paroxysmalem, persistierendem und permanentem VHF. Eine genauere Charakterisierung, auch mithilfe einer Evaluation der Vorhofflimmerlast, spielt sowohl in der Wissenschaft als auch im klinischen Alltag eine zunehmende Rolle. Wearables, insbesondere mit der Möglichkeit einer passiven (semi-)kontinuierlichen Aufzeichnung, können hier zur genaueren Quantifizierung beitragen. Primär bei Patient:innen mit bereits etablierter Vorhofflimmerdiagnose kann die Evaluation der Vorhofflimmerlast beispielsweise zur Erfolgskontrolle einer antiarrhythmischen Therapie, sei es medikamentös oder interventionell, eingesetzt werden. Offen bleiben jedoch noch wichtige Fragestellungen: Neben einer einheitlichen, evidenzbasierten Definition der Vorhofflimmerlast müssen auch klinisch relevante Cut-off-Werte sowie daraus resultierende therapeutische Konsequenzen (z. B. eines subklinischen Vorhofflimmerns) erarbeitet werden. Zudem sollte eine Etablierung und Evaluation von Versorgungsstrukturen zur Auswertung und klinischen Anwendung der Vorhofflimmerlast, insbesondere unter Einbezug von mittels Wearables erhobenen Daten, stattfinden.
Autres résumés
Type: Publisher
(ger)
Die Charakterisierung von Vorhofflimmern (VHF) entsprechend der aktuellen Leitlinien bezieht sich kategorisch auf die Differenzierung zwischen paroxysmalem, persistierendem und permanentem VHF. Eine genauere Charakterisierung, auch mithilfe einer Evaluation der Vorhofflimmerlast, spielt sowohl in der Wissenschaft als auch im klinischen Alltag eine zunehmende Rolle. Wearables, insbesondere mit der Möglichkeit einer passiven (semi-)kontinuierlichen Aufzeichnung, können hier zur genaueren Quantifizierung beitragen. Primär bei Patient:innen mit bereits etablierter Vorhofflimmerdiagnose kann die Evaluation der Vorhofflimmerlast beispielsweise zur Erfolgskontrolle einer antiarrhythmischen Therapie, sei es medikamentös oder interventionell, eingesetzt werden. Offen bleiben jedoch noch wichtige Fragestellungen: Neben einer einheitlichen, evidenzbasierten Definition der Vorhofflimmerlast müssen auch klinisch relevante Cut-off-Werte sowie daraus resultierende therapeutische Konsequenzen (z. B. eines subklinischen Vorhofflimmerns) erarbeitet werden. Zudem sollte eine Etablierung und Evaluation von Versorgungsstrukturen zur Auswertung und klinischen Anwendung der Vorhofflimmerlast, insbesondere unter Einbezug von mittels Wearables erhobenen Daten, stattfinden.
Identifiants
pubmed: 38334830
doi: 10.1007/s00399-024-00995-2
pii: 10.1007/s00399-024-00995-2
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Svennberg E, Caiani EG, Bruining N, Desteghe L, Han JK, Narayan SM, Rademakers FE, Sanders P, Duncker D (2023) The digital journey: 25 years of digital development in electrophysiology from an Europace perspective. Europace. https://doi.org/10.1093/europace/euad176
doi: 10.1093/europace/euad176
pubmed: 37622574
pmcid: 10450797
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G‑A, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J‑P, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Kirchhof P, Kühne M, Aboyans V, Ahlsson A, Balsam P, Bauersachs J, Benussi S, Brandes A, Braunschweig F, Camm AJ, Capodanno D, Casadei B, Conen D, Crijns HJGM, Delgado V, Dobrev D, Drexel H, Eckardt L, Fitzsimons D, Folliguet T, Gale CP, Gorenek B, Haeusler KG, Heidbuchel H, Iung B, Katus HA, Kotecha D, Landmesser U, Leclercq C, Lewis BS, Mascherbauer J, Merino JL, Merkely B, Mont L, Mueller C, Nagy KV, Oldgren J, Pavlović N, Pedretti RFE, Petersen SE, Piccini JP, Popescu BA, Pürerfellner H, Richter DJ, Roffi M, Rubboli A, Scherr D, Schnabel RB, Simpson IA, Shlyakhto E, Sinner MF, Steffel J, Sousa-Uva M, Suwalski P, Svetlosak M, Touyz RM, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G‑A, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J‑P, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Watkins CL (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa612
doi: 10.1093/eurheartj/ehaa612
pubmed: 34875053
pmcid: 8014526
Hermans BJM, Weberndörfer V, Bijvoet GP, Chaldoupi S‑M, Linz D (2022) New concepts in atrial fibrillation pathophysiology. Herzschr Elektrophys 33:362–366. https://doi.org/10.1007/s00399-022-00897-1
doi: 10.1007/s00399-022-00897-1
De With RR, Erküner Ö, Rienstra M, Nguyen B‑O, Körver FWJ, Linz D, Ten HC, Spronk H, Kroon AA, Maass AH, Blaauw Y, Tieleman RG, Hemels MEW, de Groot JR, Elvan A, de Melis M, Scheerder COS, Al-Jazairi MIH, Schotten U, Luermans JGLM, Crijns HJGM, Van Gelder IC (2020) Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace 22:1162–1172. https://doi.org/10.1093/europace/euaa123
doi: 10.1093/europace/euaa123
pubmed: 32642768
pmcid: 7400474
van de Lande ME, Rama RS, Koldenhof T, Arita VA, Nguyen B‑O, van Deutekom C, Weberndorfer V, Crijns HJGM, Hemels MEW, Tieleman RG, de Melis M, Schotten U, Linz D, Van Gelder IC, Rienstra M (2023) Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study. Europace. https://doi.org/10.1093/europace/euad058
doi: 10.1093/europace/euad058
pubmed: 37847230
pmcid: 10580370
Betz K, van der Velden R, Gawalko M, Hermans A, Pluymaekers N, Hillmann HAK, Hendriks J, Duncker D, Linz D (2021) Interpretation der Photoplethysmographie: Schritt für Schritt. Herzschr Elektrophys 32:406–411. https://doi.org/10.1007/s00399-021-00795-y
doi: 10.1007/s00399-021-00795-y
van der Velden RMJ, Verhaert DVM, Hermans ANL, Duncker D, Manninger M, Betz K, Gawalko M, Desteghe L, Pisters R, Hemels M, Pison L, Sohaib A, Sultan A, Steven D, Wijtvliet P, Gupta D, Svennberg E, Luermans JCLM, Chaldoupi M, Vernooy K, den Uijl D, Lodzinski P, Jansen WPJ, Eckstein J, Bollmann A, Vandervoort P, Crijns HJGM, Tieleman R, Heidbuchel H, Pluymaekers NAHA, Hendriks JM, Linz D (2021) The photoplethysmography dictionary: practical guidance on signal interpretation and clinical scenarios from Telecheck-AF. Eur Heart J. https://doi.org/10.1093/ehjdh/ztab050
doi: 10.1093/ehjdh/ztab050
Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, Boriani G, Burri H, Conte G, Deharo JC, Deneke T, Drossart I, Duncker D, Han JK, Heidbuchel H, Jais P, de Oliviera Figueiredo MJ, Linz D, Lip GYH, Malaczynska-Rajpold K, Márquez M, Ploem C, Soejima K, Stiles MK, Wierda E, Vernooy K, Leclercq C, Meyer C, Pisani C, Pak HN, Gupta D, Pürerfellner H, Crijns HJGM, Chavez EA, Willems S, Waldmann V, Dekker L, Wan E, Kavoor P, Turagam MK, Sinner M (2022) How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace 24:979–1005. https://doi.org/10.1093/europace/euac038
doi: 10.1093/europace/euac038
pubmed: 35368065
Proesmans T, Mortelmans C, Van Haelst R, Verbrugge F, Vandervoort P, Vaes B (2019) Mobile phone-based use of the photoplethysmography technique to detect atrial fibrillation in primary care: diagnostic accuracy study of the fibricheck app. JMIR Mhealth Uhealth. https://doi.org/10.2196/12284
doi: 10.2196/12284
pubmed: 30916656
pmcid: 6456825
Hermans ANL, Isaksen JL et al (2023) Accuracy of continuous photoplethysmography-based 1 min mean heart rate assessment during atrial fibrillation. Europace 25:835–844. https://doi.org/10.1093/europace/euad011
doi: 10.1093/europace/euad011
pubmed: 36748247
pmcid: 10062358
Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH, Brandes A, Crystal E, Costantini O, Sandhu RK, Parkash R, Connolly SJ, Hohnloser SH, Healey JS (2012) Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 9:1241–1246. https://doi.org/10.1016/j.hrthm.2012.03.017
doi: 10.1016/j.hrthm.2012.03.017
pubmed: 22440154
Hermans ANL, Gawalko M, Pluymaekers NAHA, Dinh T, Weijs B, van Mourik MJW, Vorstermans B, den Uijl DW, Opsteyn L, Snippe H, Vernooy K, Crijns HJGM, Linz D, Luermans JGLM (2021) Long-term intermittent versus short continuous heart rhythm monitoring for the detection of atrial fibrillation recurrences after catheter ablation. Int J Cardiol 329:105–112. https://doi.org/10.1016/j.ijcard.2020.12.077
doi: 10.1016/j.ijcard.2020.12.077
pubmed: 33412184
Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, Krieger D, Holst AG, Nielsen JB, Brandes A, Svendsen JH (2020) Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation. Circulation 141:1510–1522. https://doi.org/10.1161/CIRCULATIONAHA.119.044407
doi: 10.1161/CIRCULATIONAHA.119.044407
pubmed: 32114796
Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, Noseworthy PA, Perez MV, Turakhia MP (2018) Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American heart association. Circulation. https://doi.org/10.1161/CIR.0000000000000568
doi: 10.1161/CIR.0000000000000568
pubmed: 30571346
pmcid: 6366943
Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB (2013) Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 34:2464–2471. https://doi.org/10.1093/eurheartj/eht135
doi: 10.1093/eurheartj/eht135
pubmed: 23594592
Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KAA, Califf RM, Piccini JP (2015) Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 36:288–296. https://doi.org/10.1093/eurheartj/ehu359
doi: 10.1093/eurheartj/ehu359
pubmed: 25209598
Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E (2017) Stroke and mortality risk in patients with various patterns of atrial fibrillation. Circ Arrhythm Electrophysiol. https://doi.org/10.1161/CIRCEP.116.004267
doi: 10.1161/CIRCEP.116.004267
pubmed: 28314849
Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke. Circulation 107:1614–1619. https://doi.org/10.1161/01.CIR.0000057981.70380.45
doi: 10.1161/01.CIR.0000057981.70380.45
pubmed: 12668495
Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SKG, Bauer WR, Paul V, Sack S (2012) Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 14:230–237. https://doi.org/10.1093/europace/eur293
doi: 10.1093/europace/eur293
pubmed: 21933802
Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC (2015) Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm 12:2368–2375. https://doi.org/10.1016/j.hrthm.2015.07.007
doi: 10.1016/j.hrthm.2015.07.007
pubmed: 26164377
Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, Bertaglia E, Blomstrom Lundqvist C, Borlich M, Brandes A, Cabanelas N, Calvert M, Chlouverakis G, Dan G‑A, de Groot JR, Dichtl W, Kravchuk B, Lubiński A, Marijon E, Merkely B, Mont L, Ozga A‑K, Rajappan K, Sarkozy A, Scherr D, Sznajder R, Velchev V, Wichterle D, Sehner S, Simantirakis E, Lip GYH, Vardas P, Schotten U, Zapf A (2023) Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 389:1167–1179. https://doi.org/10.1056/NEJMoa2303062
doi: 10.1056/NEJMoa2303062
pubmed: 37622677
Becher N, Toennis T, Bertaglia E, Blomström-Lundqvist C, Brandes A, Cabanelas N, Calvert M, Camm AJ, Chlouverakis G, Dan G‑A, Dichtl W, Diener HC, Fierenz A, Goette A, de Groot JR, Hermans ANL, Lip GYH, Lubinski A, Marijon E, Merkely B, Mont L, Ozga A‑K, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Sehner S, Simantirakis E, Vardas P, Velchev V, Wichterle D, Zapf A, Kirchhof P (2023) Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥ 24 hours. Eur Heart J. https://doi.org/10.1093/eurheartj/ehad771
doi: 10.1093/eurheartj/ehad771
pubmed: 37956458
Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie DH, Boriani G, Camm AJ, Conen D, Erath JW, Gold MR, Hohnloser SH, Ip J, Kautzner J, Kutyifa V, Linde C, Mabo P, Mairesse G, Benezet Mazuecos J, Cosedis Nielsen J, Philippon F, Proietti M, Sticherling C, Wong JA, Wright DJ, Zarraga IG, Coutts SB, Kaplan A, Pombo M, Ayala-Paredes F, Xu L, Simek K, Nevills S, Mian R, Connolly SJ (2023) Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. https://doi.org/10.1056/NEJMoa2310234
doi: 10.1056/NEJMoa2310234
pubmed: 37952132
McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf A, Alings M, Connolly SJ, Kirchhof P, Lopes RD (2023) Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.123.067512
doi: 10.1161/CIRCULATIONAHA.123.067512
pubmed: 38126206
Nielsen JC, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Pehrson SM, Englund A, Hartikainen J, Mortensen LS, Hansen PS (2017) Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5‑year outcome in a randomised clinical trial. Heart 103:368–376. https://doi.org/10.1136/heartjnl-2016-309781
doi: 10.1136/heartjnl-2016-309781
pubmed: 27566295
Suman-Horduna I, Roy D, Frasure-Smith N, Talajic M, Lespérance F, Blondeau L, Dorian P, Khairy P (2013) Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 61:455–460. https://doi.org/10.1016/j.jacc.2012.10.031
doi: 10.1016/j.jacc.2012.10.031
pubmed: 23265334
Jenkins LS, Brodsky M, Schron E, Chung M, Rocco T Jr, Lader E, Constantine M, Sheppard R, Holmes D, Mateski D, Floden L, Prasun M, Greene HL, Shemanski L (2005) Quality of life in atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 149:112–120. https://doi.org/10.1016/j.ahj.2004.03.065
doi: 10.1016/j.ahj.2004.03.065
pubmed: 15660042
Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, McGavigan AD (2016) The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 37:1591–1602. https://doi.org/10.1093/eurheartj/ehw007
doi: 10.1093/eurheartj/ehw007
pubmed: 26888184
Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P (2013) Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation. JAMA 310:2050. https://doi.org/10.1001/jama.2013.280521
doi: 10.1001/jama.2013.280521
pubmed: 24240932
Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P (2015) Long-term effect of goal-directed weight management in an atrial fibrillation cohort. J Am Coll Cardiol 65:2159–2169. https://doi.org/10.1016/j.jacc.2015.03.002
doi: 10.1016/j.jacc.2015.03.002
pubmed: 25792361
Andrade JG, Yao RRJ, Deyell MW, Hawkins NM, Rizkallah J, Jolly U, Khoo C, Raymond J‑M, McKinney J, Cheung C, Steinberg C, Ha A, Ramanathan K, Luong C, Glover B, Verma A, Macle L, Khairy P (2020) Clinical assessment of AF pattern is poorly correlated with AF burden and post ablation outcomes: a CIRCA-DOSE sub-study. J Electrocardiol 60:159–164. https://doi.org/10.1016/j.jelectrocard.2020.03.008
doi: 10.1016/j.jelectrocard.2020.03.008
pubmed: 32371199
Andrade JG, Deyell MW, Verma A, Macle L, Champagne J, Leong-Sit P, Novak P, Badra-Verdu M, Sapp J, Khairy P, Nattel S (2020) Association of atrial fibrillation episode duration with arrhythmia recurrence following ablation. JAMA Netw Open 3:e208748. https://doi.org/10.1001/jamanetworkopen.2020.8748
doi: 10.1001/jamanetworkopen.2020.8748
pubmed: 32614422
pmcid: 7333024
Reissenberger P, Serfözö P, Piper D, Juchler N, Glanzmann S, Gram J, Hensler K, Tonidandel H, Börlin E, D’Souza M, Badertscher P, Eckstein J (2023) Determine atrial fibrillation burden with a photoplethysmographic mobile sensor: the atrial fibrillation burden trial: detection and quantification of episodes of atrial fibrillation using a cloud analytics service connected to a wearable with photoplethysmographic sensor. Eur Heart J 4:402–410. https://doi.org/10.1093/ehjdh/ztad039
doi: 10.1093/ehjdh/ztad039
Wasserlauf J, You C, Patel R, Valys A, Albert D, Passman R (2019) Smartwatch performance for the detection and quantification of atrial fibrillation. Circ Arrhythm Electrophysiol. https://doi.org/10.1161/CIRCEP.118.006834
doi: 10.1161/CIRCEP.118.006834
pubmed: 31113234
Chang P‑C, Wen M‑S, Chou C‑C, Wang C‑C, Hung K‑C (2022) Atrial fibrillation detection using ambulatory smartwatch photoplethysmography and validation with simultaneous holter recording. Am Heart J 247:55–62. https://doi.org/10.1016/j.ahj.2022.02.002
doi: 10.1016/j.ahj.2022.02.002
pubmed: 35131229
Zhu L, Nathan V, Kuang J, Kim J, Avram R, Olgin J, Gao J (2022) Atrial fibrillation detection and atrial fibrillation burden estimation via wearables. IEEE J Biomed Health Inform 26:2063–2074. https://doi.org/10.1109/JBHI.2021.3131984
doi: 10.1109/JBHI.2021.3131984
pubmed: 34855603
Hillmann HAK, Soltani S, Mueller-Leisse J, Hohmann S, Duncker D (2022) Cardiac rhythm monitoring using wearables for clinical guidance before and after catheter ablation. J Clin Med 11:2428. https://doi.org/10.3390/jcm11092428
doi: 10.3390/jcm11092428
pubmed: 35566556
pmcid: 9100087
Lawin D, Kuhn S, Schulze Lammers S, Lawrenz T, Stellbrink C (2022) Use of digital health applications for the detection of atrial fibrillation. Herzschr Elektrophys 33:373–379. https://doi.org/10.1007/s00399-022-00888-2
doi: 10.1007/s00399-022-00888-2
Manninger M, Hermans ANL, Caracioni A‑A, Rohrer U, Eberl A‑S, Vernooy K, Zirlik A, Linz D, Scherr D (2023) Photoplethysmography-documented atrial fibrillation in the first week after catheter ablation is associated with lower success rates. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2023.1199630
doi: 10.3389/fcvm.2023.1199630
pubmed: 37424905
pmcid: 10324576
Gunawardene M, Hartmann J, Willems S (2023) Asymptomatisches Vorhofflimmern. Herzschr Elektrophys 34:122–130. https://doi.org/10.1007/s00399-023-00933-8
doi: 10.1007/s00399-023-00933-8
Andrade JG, Deyell MW, Bennett R, Macle L (2023) Assessment and management of asymptomatic atrial fibrillation. Heart. https://doi.org/10.1136/heartjnl-2023-322428
doi: 10.1136/heartjnl-2023-322428
pubmed: 37507214